204 related articles for article (PubMed ID: 37193898)
21. Risedronate and Methotrexate Are High-Affinity Inhibitors of New Delhi Metallo-β-Lactamase-1 (NDM-1): A Drug Repurposing Approach.
Muteeb G; Alsultan A; Farhan M; Aatif M
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209073
[TBL] [Abstract][Full Text] [Related]
22. Biochemical and computational evaluation of Triptolide-induced cytotoxicity against NSCLC.
Hamdi AM; Jiang ZZ; Guerram M; Yousef BA; Hassan HM; Ling JW; Zhang LY
Biomed Pharmacother; 2018 Jul; 103():1557-1566. PubMed ID: 29864943
[TBL] [Abstract][Full Text] [Related]
23. AKT Inhibitors: The Road Ahead to Computational Modeling-Guided Discovery.
Halder AK; Cordeiro MNDS
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920446
[TBL] [Abstract][Full Text] [Related]
24. In Silico Identification of Possible Inhibitors for Protein Kinase B (PknB) of
Vieira TF; Martins FG; Moreira JP; Barbosa T; Sousa SF
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684743
[TBL] [Abstract][Full Text] [Related]
25. Computational insights into the inhibitory mechanism of human AKT1 by an orally active inhibitor, MK-2206.
Rehan M; Beg MA; Parveen S; Damanhouri GA; Zaher GF
PLoS One; 2014; 9(10):e109705. PubMed ID: 25329478
[TBL] [Abstract][Full Text] [Related]
26. Drug repurposing combined with MM/PBSA based validation strategies towards MEK inhibitors screening.
Thirunavukkarasu MK; Karuppasamy R
J Biomol Struct Dyn; 2022; 40(22):12392-12403. PubMed ID: 34459701
[TBL] [Abstract][Full Text] [Related]
27. Pharmacophore based virtual screening, molecular docking and molecular dynamic simulation studies for finding ROS1 kinase inhibitors as potential drug molecules.
Vanajothi R; Vedagiri H; Al-Ansari MM; Al-Humaid LA; Kumpati P
J Biomol Struct Dyn; 2022 May; 40(8):3385-3399. PubMed ID: 33200682
[TBL] [Abstract][Full Text] [Related]
28. Pharmacophore-Model-Based Drug Repurposing for the Identification of the Potential Inhibitors Targeting the Allosteric Site in Dengue Virus NS5 RNA-Dependent RNA Polymerase.
Kumar S; Bajrai LH; Faizo AA; Khateb AM; Alkhaldy AA; Rana R; Azhar EI; Dwivedi VD
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016449
[TBL] [Abstract][Full Text] [Related]
29. In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations.
SarathKumar B; Lakshmi BS
J Mol Model; 2019 Aug; 25(9):272. PubMed ID: 31451955
[TBL] [Abstract][Full Text] [Related]
30. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
31. Exploring species-specific inhibitors with multiple target sites on
Yuce M; Sarica Z; Ates B; Kurkcuoglu O
J Biomol Struct Dyn; 2023 May; 41(8):3496-3510. PubMed ID: 35302925
[TBL] [Abstract][Full Text] [Related]
32. Exploring allosteric hits of the NS2B-NS3 protease of DENV2 by structure-guided screening.
Gangopadhyay A; Saha A
Comput Biol Chem; 2023 Jun; 104():107876. PubMed ID: 37141792
[TBL] [Abstract][Full Text] [Related]
33. Development of triple mutant T790M/C797S allosteric EGFR inhibitors: a computational approach.
Karnik KS; Sarkate AP; Lokwani DK; Narula IS; Burra PVLS; Wakte PS
J Biomol Struct Dyn; 2021 Sep; 39(15):5376-5398. PubMed ID: 32608331
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Kakarala KK; Jamil K
J Biomol Struct Dyn; 2022 Sep; 40(15):6889-6909. PubMed ID: 33682622
[TBL] [Abstract][Full Text] [Related]
35. Insight into the structural mechanism for PKBα allosteric inhibition by molecular dynamics simulations and free energy calculations.
Chen SF; Cao Y; Han S; Chen JZ
J Mol Graph Model; 2014 Mar; 48():36-46. PubMed ID: 24374242
[TBL] [Abstract][Full Text] [Related]
36. Akt Pathway Inhibitors.
Uko NE; Güner OF; Matesic DF; Bowen JP
Curr Top Med Chem; 2020; 20(10):883-900. PubMed ID: 32091335
[TBL] [Abstract][Full Text] [Related]
37. Targeting the Akt1 allosteric site to identify novel scaffolds through virtual screening.
Yilmaz OG; Olmez EO; Ulgen KO
Comput Biol Chem; 2014 Feb; 48():1-13. PubMed ID: 24291487
[TBL] [Abstract][Full Text] [Related]
38. Computational targeting of allosteric site of MEK1 by quinoline-based molecules.
Singh R; Bhardwaj VK; Purohit R
Cell Biochem Funct; 2022 Jul; 40(5):481-490. PubMed ID: 35604288
[TBL] [Abstract][Full Text] [Related]
39. Mcl-1 Interacts with Akt to Promote Lung Cancer Progression.
Chen G; Park D; Magis AT; Behera M; Ramalingam SS; Owonikoko TK; Sica GL; Ye K; Zhang C; Chen Z; Curran WJ; Deng X
Cancer Res; 2019 Dec; 79(24):6126-6138. PubMed ID: 31662324
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
Li J; Deng H; Hu M; Fang Y; Vaughn A; Cai X; Xu L; Wan W; Li Z; Chen S; Yang X; Wu S; Xiao J
Oncotarget; 2015 Mar; 6(9):6749-61. PubMed ID: 25730907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
